Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized trial of LC16 smallpox vaccine for mpox prevention in high-risk adults
jRCT1031230137Completed
- Sponsor
- Ministry of Health, Labour and Welfare
- Start
- Jun 2023
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised trial of lc16m8 in mpox (2 arms), sponsored by Ministry of Health, Labour and Welfare. Primary endpoint: Prophylactic effectiveness of LC16 against the development of mpox. Started Jun 2023; status: completed.
02
Drugs
lc16m8
03
Conditions
mpox
Beyond the preview
Go deeper on jRCT1031230137.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1031230137.